Raymond J. Carroll Texas A&M University LOCF and MMRM: Thoughts on Comparisons.

Slides:



Advertisements
Similar presentations
Introduction to Hypothesis Testing
Advertisements

Tests About a Population Mean
Asthma Trial – a double blinded, randomized, placebo-controlled study Team Moser: Jing Dong Yan Yan Wu Haipeng Yao.
Holland on Rubin’s Model Part II. Formalizing These Intuitions. In the 1920 ’ s and 30 ’ s Jerzy Neyman, a Polish statistician, developed a mathematical.
1 QOL in oncology clinical trials: Now that we have the data what do we do?
1-1 Copyright © 2015, 2010, 2007 Pearson Education, Inc. Chapter 21, Slide 1 Chapter 21 Comparing Two Proportions.
Chapter 7: Data for Decisions Lesson Plan
Bayesian posterior predictive probability - what do interim analyses mean for decision making? Oscar Della Pasqua & Gijs Santen Clinical Pharmacology Modelling.
Testing Hypotheses About Proportions Chapter 20. Hypotheses Hypotheses are working models that we adopt temporarily. Our starting hypothesis is called.
Copyright © 2010, 2007, 2004 Pearson Education, Inc. Chapter 13 Experiments and Observational Studies.
Missing Data and Repeated Measurements
Common Problems in Writing Statistical Plan of Clinical Trial Protocol Liying XU CCTER CUHK.
Sampling and Experimental Control Goals of clinical research is to make generalizations beyond the individual studied to others with similar conditions.
Clinical Trials Hanyan Yang
Sample Size Determination
Sample Size Determination Ziad Taib March 7, 2014.
Part 3 of 3 By: Danielle Davidov, PhD & Steve Davis, MSW, MPA INTRODUCTION TO RESEARCH: SAMPLING & DESIGN.
Marshall University School of Medicine Department of Biochemistry and Microbiology BMS 617 Lecture 10: Survival Curves Marshall University Genomics Core.
AP Statistics Section 5.2 A Designing Experiments
Clinical Trials. What is a clinical trial? Clinical trials are research studies involving people Used to find better ways to prevent, detect, and treat.
I want to test a wound treatment or educational program in my clinical setting with patient groups that are convenient or that already exist, How do I.
بسم الله الرحمن الرحيم * this presentation about :- “experimental design “ * Induced to :- Dr Aidah Abu Elsoud Alkaissi * Prepared by :- 1)-Hamsa karof.
Reading Scientific Papers Shimae Soheilipour
The Mimix Command Reference Based Multiple Imputation For Sensitivity Analysis of Longitudinal Trials with Protocol Deviation Suzie Cro EMERGE.
Copyright © 2010 Pearson Education, Inc. Chapter 13 Experiments and Observational Studies.
Experiments and Observational Studies. Observational Studies In an observational study, researchers don’t assign choices; they simply observe them. look.
Copyright © 2010 Pearson Education, Inc. Slide
Chapter 13 Observational Studies & Experimental Design.
Copyright © 2007 Pearson Education, Inc. Publishing as Pearson Addison-Wesley Chapter 13 Experiments and Observational Studies.
Biostatistics for Coordinators Peter D. Christenson REI and GCRC Biostatistician GCRC Lecture Series: Strategies for Successful Clinical Trials Session.
What’s in the news right now related to science???? Flesh eating bacteria.
Comparing Two Proportions
Study Designs Afshin Ostovar Bushehr University of Medical Sciences Bushehr, /4/20151.
Slide 13-1 Copyright © 2004 Pearson Education, Inc.
Biostatistics Case Studies 2007 Peter D. Christenson Biostatistician Session 3: Incomplete Data in Longitudinal Studies.
Part III Gathering Data.
Chapter 5: Producing Data “An approximate answer to the right question is worth a good deal more than the exact answer to an approximate question.’ John.
Biostatistics Case Studies 2008 Peter D. Christenson Biostatistician Session 5: Choices for Longitudinal Data Analysis.
Copyright © 2013, 2009, and 2007, Pearson Education, Inc. Chapter 4 Gathering Data Section 4.3 Good and Poor Ways to Experiment.
Chapter 20 Testing hypotheses about proportions
Copyright © 2008 Pearson Education, Inc. Publishing as Pearson Addison-Wesley Chapter 20 Testing Hypotheses About Proportions.
Conducting A Study Designing Sample Designing Experiments Simulating Experiments Designing Sample Designing Experiments Simulating Experiments.
Copyright © 2010 Pearson Education, Inc. Chapter 22 Comparing Two Proportions.
Copyright © 2010, 2007, 2004 Pearson Education, Inc. Chapter 22 Comparing Two Proportions.
Mixed models. Concepts We are often interested in attributing the variability that is evident in data to the various categories, or classifications, of.
1 Updates on Regulatory Requirements for Missing Data Ferran Torres, MD, PhD Hospital Clinic Barcelona Universitat Autònoma de Barcelona.
Biostatistics Case Studies 2006 Peter D. Christenson Biostatistician Session 4: An Alternative to Last-Observation-Carried-Forward:
Copyright © 2010, 2007, 2004 Pearson Education, Inc. Chapter 24 Comparing Means.
1 Study Design Issues and Considerations in HUS Trials Yan Wang, Ph.D. Statistical Reviewer Division of Biometrics IV OB/OTS/CDER/FDA April 12, 2007.
The Practice of Statistics, 5th Edition Starnes, Tabor, Yates, Moore Bedford Freeman Worth Publishers CHAPTER 4 Designing Studies 4.2Experiments.
Simulation Study for Longitudinal Data with Nonignorable Missing Data Rong Liu, PhD Candidate Dr. Ramakrishnan, Advisor Department of Biostatistics Virginia.
1 Handling of Missing Data. A regulatory view Ferran Torres, MD, PhD IDIBAPS. Hospital Clinic Barcelona Autonomous University of Barcelona (UAB)
Experimental Control Definition Is a predictable change in behavior (dependent variable) that can be reliably produced by the systematic manipulation.
Organization of statistical investigation. Medical Statistics Commonly the word statistics means the arranging of data into charts, tables, and graphs.
Biostatistics Case Studies 2006 Peter D. Christenson Biostatistician Session 3: An Alternative to Last-Observation-Carried-Forward:
1 Chapter 6 SAMPLE SIZE ISSUES Ref: Lachin, Controlled Clinical Trials 2:93-113, 1981.
Statistics 22 Comparing Two Proportions. Comparisons between two percentages are much more common than questions about isolated percentages. And they.
Statistics 20 Testing Hypothesis and Proportions.
1 Statistical Issues in NDA Laura Lu, Ph.D FDA/CDER.
An Alternative to Data Imputation in Analgesic Clinical Trials David Petullo, Thomas Permutt, Feng Li Division of Biometrics II, Office of Biostatistics.
Comparing Two Proportions
Crucial Statistical Caveats for Percutaneous Valve Trials
Aligning Estimands and Estimators – A Case Study Sept 13, 2018 Elena Polverejan Vladimir Dragalin Quantitative Sciences Janssen R&D, Johnson & Johnson.
Comparing Two Proportions
11/20/2018 Study Types.
Comparing Two Proportions
Common Problems in Writing Statistical Plan of Clinical Trial Protocol
What Do We Know About Estimators for the Treatment Policy Estimand
How Should We Select and Define Trial Estimands
2019 Joint Statistical Meetings at Denver
Presentation transcript:

Raymond J. Carroll Texas A&M University LOCF and MMRM: Thoughts on Comparisons

Outline Brief rehash of the talks comparing LOCF and mixed models Defense of LOCF as a clinically relevant endpoint Conclusions

Bob O’Neill “In protocol planning, assume that monotonic missing data, if it occurs, is likely informative”, at least depending on treatment At the very least, this means missing at random (MAR) It makes no sense (to me!) to use as a primary analysis a method that is known to fail under the simplest MAR conditions.

Bob O’Neill Problem: “how to specify in the protocol the primary strategy for dealing with missing data - if you presume that it will be informative - and you have not observed the data yet” “Decide what data will be collected that will allow for conditioning on factors that matter to address bias adjustments” Message to me: the more and better data that is gathered, the simpler the analysis that can be reasonably specified.

Bob O’Neill “There is NO strategy which is adequate for all different combinations of dropout mechanisms, drop-out rates or less similar courses of disease and no adequate recommendations can be given” Amen!

Bob O’Neill “Decide what data will be collected that will allow for conditioning on factors that matter to address bias adjustments” In addition, “If possible, collect data on all subjects until the trial is completed, even if withdrawn from trial ” I’d say: try to collect data after dropout! The fact is that investigators can, with enough effort and expense, collect more data post dropout: a major point in what follows

Geert Mohlenberghs and Craig Mallinckrodt: LOCF versus Mixed Models LOCF essentially never theoretically justified for endpoint and baseline comparisons, since as Bob O’Neill says, MAR or worse is the rule Difficult to understand why it is used for this purpose Mixed Models are theoretically justified under readily explicated assumptions Mixed model software makes it possible to write a priori defined protocols

Review of LOCF versus Mixed Models Mixed models less sensitive to informative missingness (NMAR) than LOCF There is no single, nor can there ever be a single analysis for NMAR data (Bob O’Neill makes this point as well) Investigators should strive to collect data on dropouts, and follow them up.

LOCF as a Clinically Relevant Endpoint One defense of LOCF is that it is said to be measuring a clinically relevant endpoint, albeit a different one from what MMRM is measuring We all know it is inappropriate for a endpoint/baseline comparison

LOCF as a Clinically Relevant Endpoint One defense of LOCF is that it is said to be measuring a clinically relevant endpoint, albeit a different one from what MMRM is measuring That is, what is relevant is what the physician sees while the patient is in the study Thus, the argument goes, this is not a matter of statistics, it is a matter of medical science The argument sounds great, but is bogus

LOCF as a Clinically Relevant Endpoint LOCF in this sense violates the fundamental basis of statistics When we compare populations, we compare them on the basis of a parameter LOCF has no physical parameter, because its result (mean change) is subject to investigator manipulation (More later) Thus, as a statistical method, LOCF makes no sense

LOCF as a Clinically Relevant Endpoint LOCF has no physical parameter, because its result (mean change) is subject to investigator manipulation Specifically, what LOCF measures differs depending on how much effort is spent in obtaining follow up data

LOCF as a Clinically Relevant Endpoint Time Placebo Treatment Endpoint Investigators strive mightily to keep patients in the study or to follow them up No treatment effect

LOCF as a Clinically Relevant Endpoint Time Placebo Treatment Endpoint Investigators skip follow up and lots of placebos drop out early (dashed line) Nice big treatment effect What is LOCF making inference about? No one knows!

Conclusions Gather more data, either to make simpler analysis reasonable or to obviate need for NMAR analysis Post dropout follow up? The “clinically relevant endpoint” argument for LOCF is all hat and no cattle No single NMAR analysis will ever exist